¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"Review of public data use."¿¡ ´ëÇÑ ´ëÇÑÀÇÇù ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
drug utilization review
¾à¹°»ç¿ë°ËÅä
Institutional Review Board
»ý¸íÀ±¸®À§¿øÈ¸
retrospective review
ÈÄÇâÆò°¡
review
°ËÅä, Æò°¡
review of system
ü°èº°¹®Áø
data
ÀÚ·á
data acquisition
ÀÚ·á¼öÁý
data clipping
ÀÚ·áÀý´Ü
data clipping artifact
ÀÚ·áÀý´ÜÀΰø¹°
data display
ÀÚ·áÇ¥½Ã
data processing
ÀÚ·áó¸®
material safety data sheet
¹°Áú¾ÈÀüÀÚ·á¿ëÁö
public access defibrillator
ÀϹݴëÁß¼¼µ¿Á¦°Å±â
public antigen
°øÀ¯Ç׿ø
public exposure
°ø°øÇÇÆø, °ø°ø³ëÃâ
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
10
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
review
°ËÅä, Æò°¡
data
ÀÚ·á
baseline data
±âÃÊÀÚ·á
public health agency
°øÁߺ¸°Ç±â°ü
public health center
º¸°Ç¼Ò
public exposure
°øÁßÇÇÆø, °øÁß³ëÃâ
public health
°øÁߺ¸°Ç
public hazard
°øÇØ
public hygiene
°øÁßÀ§»ý
public health service
°øÁߺ¸°Ç»ç¾÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
concurrent review
ÀÔ¿øÁßÁ¶»ç, µ¿½ÃÆò°¡
drug utilization review
¾à¹°»ç¿ë°ËÅä
review
Á¶»ç, Æò°¡
retrospective review
Åð¿øÈÄÁ¶»ç, »çÈÄÆò°¡
utilization review
ÀÇ·áÀ̿뵵Á¶»ç
data acquisition
ÀÚ·á¼öÁý
data clipping artifact
ÀÚ·áÀý´ÜÀΰø¹°
baseline data
±âÃÊÀÚ·á
blood gas data
Ç÷¾×°¡½º°Ë»çÀÚ·á
clinical data
ÀÓ»óÀÚ·á
data clipping
ÀÚ·áÀý´Ü
data
ÀÚ·á, Àç·á, µ¥ÀÌÅÍ
data display
ÀÚ·áÇ¥½Ã
data processing
ÀÚ·áó¸®
discrete data
ÀÌ»êÀÚ·á
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
professional standard review organization(PSRO)
ÀÇ·áÆò°¡¿ø.
hallucinogen use disorder
ȯ°¢Á¦»ç¿ëÀå¾Ö(º´)(ü³ÊÆð¥ÞÅéÄî¡äô)
harmful use
À¯ÇØ<ÇØ·Î¿î>»ç¿ë(êóúªÞÅéÄ)
phencyclidine use disorder
Ææ½ÎÀÌŬ¸®µò »ç¿ëÀå¾Ö(º´)
Clinical data
ÀÓ»óÀÚ·á
Data analysis
Á¤º¸ºÐ¼®
MSDS => Material Safety Data Sheet
¹°Áú¾ÈÀüÀÚ·á¿ëÁö
identifying data
½Å»óÀÚ·á
PSTN (public switched telephone network)
°øÁß ÀüȸÁ, °øÁß ÀüÈ ±³È¯¸Á
antigen, public
ÀϹÝÇ׿ø, °øÅëÇ׿øcf.private antigen
public antigen
°øÅëÇ׿ø
public antigen
ÀϹÝÇ׿ø, °øÅëÇ׿ø cf.private antigen
public exposure
°øÁßÇÇÆø
public hazard =p. nuisance
°øÇØ(ËÌ´).
public health
°øÁߺ¸°Ç(ÇÐ)(ËÌ¡ËÓ˧̰).
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
concurrent review
ÀÔ¿ø Áß Á¶»ç, µ¿½ÃÆò°¡
drug utilization review
¾à¹°»ç¿ë °ËÅä.
life review
Àλý¹ÝÃß(ìÑßæÚãõÖ)
peer review
µ¿·á Àç°Ë(î¢Ëþ)
peer review organization(PRO)
µ¿·á½É»çÀ§¿øÈ¸.
professional standard review organization(PSRO)
ÀÇ·áÆò°¡¿ø.
retrospective review
Åð¿øÈÄ Á¶»ç, »çÈÄÆò°¡.
utilization review
ÀÇ·áÀ̿뵵 Á¶»ç.
clinical use
ÀÓ»óÀû(ÀÎ) ÀÌ¿ë
excessive use
°ú¿ë(ΦéÄ).
external use
¿Ü¿ë(èâéÄ).
hallucinogen use disorder
ȯ°¢Á¦»ç¿ëÀå¾Ö(º´)(ü³ÊÆð¥ÞÅéÄî¡äô)
harmful use
À¯ÇØ<ÇØ·Î¿î>»ç¿ë(êóúªÞÅéÄ)
internal use
³»¿ë(Ò®éÄ).
opioid use disorder
¾ÆÆí¾çÁ¦Á¦ »ç¿ëÀå¾Ö(º´).
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
1
¿µ¹®
ÇѱÛ
ÅëÇÕ°Ë»ö ¿Ï·á
´ÙÀ½